Pembrolizumab for Disease Relapse After Allogeneic HSCT
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab for the treatment of disease relapse following allogeneic hematopoietic stem cell transplantation
Blood Adv 2022 Aug 16;[EPub Ahead of Print], J Godfrey, H Liu, J Yu, M Tallarico, E Curran, AS Artz, PA Riedell, W Stock, T Karrison, C Fitzpatrick, G Venkataraman, A Cooper, SM Smith, MR Bishop, J KlineFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.